Overview Cellgate is rapidly advancing a portfolio of innovative anti-proliferation therapeutics, each with the potential to provide new treatment options for patients with diseases characterized by uncontrolled cell division, an underlying cause of many diseases-cancers, age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia, among others. Cellgate's compounds selectively inhibit the uncontrolled growth of cells associated with each condition. Two promising compounds are now progressing through clinical development, and several more are undergoing preclinical evaluation. Cellgate's lead compounds belong to a unique class of medicines known as polyamine analogs. CGC-11047, our most advanced product, is currently in clinical trials including: → a Phase II study in prostate cancer, → a Phase Ib trial in combination with standard chemotherapies inadvanced solidandhematologicaltumors, and → a Phase I clinical study in macular degeneration. CGC-11093, another anti-cancer polyamine analog compound, is in Phase I clinical studies to evaluate safety and tolerability. In early-stage clinical studies to date, Cellgate's polyamine analog compounds have been well tolerated. In addition to clinical-stage programs, Cellgate has established a preclinical pipeline derived from our proprietary libraries of polyamine analogs, naphthoquinones, porphyrin conjugates, and LSD1 inhibitors. Through our academic and industry collaborations, we are continuing to select highly active lead therapeutics from our library for cancer and other disorders such as vascular and chronic inflammatory diseases. The Cellgate management team brings more than 80 years of combined experience in the development of innovative products and successful approval by the US Food and Drug Administration of more than 10 New Drug Applications (NDAs) and Supplemental New Drug Applications (sNDAs). Our internal clinical research capability is able to streamline our product-development programs, deploying cost-effective resources for the oversight and execution of all aspects of our clinical programs. Cellgate is working with major academic institutions and clinical thought leaders, including our distinguished scientific advisory board, to ensure that our studies are designed to generate the information necessary to pave a clear path for late-stage product development. Our experience and strong financial position enables us to advance our therapeutics efficiently through clinical trials and ultimately make a significant impact on the lives of patients with these diseases. [ - ]

Overview Cellgate is rapidly advancing a portfolio of innovative anti-proliferation... [ + ]